These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 20683443)

  • 1. Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms.
    Fridlender ZG; Sun J; Singhal S; Kapoor V; Cheng G; Suzuki E; Albelda SM
    Mol Ther; 2010 Nov; 18(11):1947-59. PubMed ID: 20683443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy.
    Kim S; Buchlis G; Fridlender ZG; Sun J; Kapoor V; Cheng G; Haas A; Cheung HK; Zhang X; Corbley M; Kaiser LR; Ling L; Albelda SM
    Cancer Res; 2008 Dec; 68(24):10247-56. PubMed ID: 19074893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity.
    Suzuki E; Kapoor V; Jassar AS; Kaiser LR; Albelda SM
    Clin Cancer Res; 2005 Sep; 11(18):6713-21. PubMed ID: 16166452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy.
    Sterman DH; Alley E; Stevenson JP; Friedberg J; Metzger S; Recio A; Moon EK; Haas AR; Vachani A; Katz SI; Sun J; Heitjan DF; Hwang WT; Litzky L; Yearley JH; Tan KS; Papasavvas E; Kennedy P; Montaner LJ; Cengel KA; Simone CB; Culligan M; Langer CJ; Albelda SM
    Clin Cancer Res; 2016 Aug; 22(15):3791-800. PubMed ID: 26968202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multifunctional chimeric chaperone serves as a novel immune modulator inducing therapeutic antitumor immunity.
    Yu X; Guo C; Yi H; Qian J; Fisher PB; Subjeck JR; Wang XY
    Cancer Res; 2013 Apr; 73(7):2093-103. PubMed ID: 23333935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
    Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM
    Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoreduction surgery reduces systemic myeloid suppressor cell populations and restores intratumoral immunotherapy effectiveness.
    Predina JD; Kapoor V; Judy BF; Cheng G; Fridlender ZG; Albelda SM; Singhal S
    J Hematol Oncol; 2012 Jun; 5():34. PubMed ID: 22742411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.
    Nowak AK; Robinson BW; Lake RA
    Cancer Res; 2003 Aug; 63(15):4490-6. PubMed ID: 12907622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer immunotherapy employing an innovative strategy to enhance CD4+ T cell help in the tumor microenvironment.
    Song L; Yang MC; Knoff J; Wu TC; Hung CF
    PLoS One; 2014; 9(12):e115711. PubMed ID: 25531529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model.
    Ko HJ; Kim YJ; Kim YS; Chang WS; Ko SY; Chang SY; Sakaguchi S; Kang CY
    Cancer Res; 2007 Aug; 67(15):7477-86. PubMed ID: 17671218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of antitumor immunity in lung cancer by targeting myeloid-derived suppressor cell pathways.
    Sawant A; Schafer CC; Jin TH; Zmijewski J; Tse HM; Roth J; Sun Z; Siegal GP; Thannickal VJ; Grant SC; Ponnazhagan S; Deshane JS
    Cancer Res; 2013 Nov; 73(22):6609-20. PubMed ID: 24085788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor cell repopulation between cycles of chemotherapy is inhibited by regulatory T-cell depletion in a murine mesothelioma model.
    Wu L; Yun Z; Tagawa T; Rey-McIntyre K; Anraku M; de Perrot M
    J Thorac Oncol; 2011 Sep; 6(9):1578-86. PubMed ID: 21642867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenovirus expressing both thymidine kinase and soluble PD1 enhances antitumor immunity by strengthening CD8 T-cell response.
    Shin SP; Seo HH; Shin JH; Park HB; Lim DP; Eom HS; Bae YS; Kim IH; Choi K; Lee SJ
    Mol Ther; 2013 Mar; 21(3):688-95. PubMed ID: 23337984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic immunization and local low-dose tumor irradiation, a reinforcing combination.
    Draghiciu O; Walczak M; Hoogeboom BN; Franken KL; Melief KJ; Nijman HW; Daemen T
    Int J Cancer; 2014 Feb; 134(4):859-72. PubMed ID: 23922012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigen spreading-induced CD8+T cells confer protection against the lethal challenge of wild-type malignant mesothelioma by eliminating myeloid-derived suppressor cells.
    Yu Z; Tan Z; Lee BK; Tang J; Wu X; Cheung KW; Lo NT; Man K; Liu L; Chen Z
    Oncotarget; 2015 Oct; 6(32):32426-38. PubMed ID: 26431275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-4-1BB scFv immunogene therapy and low dose cyclophosphamide exhibit a synergistic antitumor effect in established murine lung tumors.
    Liu F; Fang C; Ye X; Lu Q; Yu DH; Zhang WW; Qi H; Xie J; Lieber A; Chen HZ
    Cancer Biol Ther; 2009 Apr; 8(8):707-13. PubMed ID: 19417562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells.
    Nowak AK; Lake RA; Marzo AL; Scott B; Heath WR; Collins EJ; Frelinger JA; Robinson BW
    J Immunol; 2003 May; 170(10):4905-13. PubMed ID: 12734333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose cisplatin converts the tumor microenvironment into a permissive state for HSVtk-induced antitumor immunity in HPV16-related tonsillar carcinoma.
    Goh AR; Shin SP; Jung NR; Ryu CH; Eom HS; Lee JH; Choi K; Lee SJ; Jung YS
    Cancer Lett; 2015 Jan; 356(2 Pt B):743-50. PubMed ID: 25449436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer.
    Hwang HC; Smythe WR; Elshami AA; Kucharczuk JC; Amin KM; Williams JP; Litzky LA; Kaiser LR; Albelda SM
    Am J Respir Cell Mol Biol; 1995 Jul; 13(1):7-16. PubMed ID: 7598939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy.
    DeLong P; Tanaka T; Kruklitis R; Henry AC; Kapoor V; Kaiser LR; Sterman DH; Albelda SM
    Cancer Res; 2003 Nov; 63(22):7845-52. PubMed ID: 14633712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.